Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome
- PMID: 36914979
- DOI: 10.1111/apt.17465
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome
Abstract
Background: Little is known about faecal incontinence (FI) in individuals with irritable bowel syndrome (IBS).
Aims: To compare characteristics of people with IBS reporting FI, compared with people with IBS who do not report FI.
Methods: We collected demographic, gastrointestinal and psychological symptoms, healthcare usage, direct healthcare costs, impact on work and activities of daily living, and quality of life data from individuals with Rome IV-defined IBS. We asked participants about FI, assigning presence or absence according to Rome-IV criteria.
Results: Of 752 participants with Rome IV IBS, 202 (26.9%) met Rome IV criteria for FI. Individuals with FI were older (p < 0.001), more likely to have IBS-D (47.0% vs. 39.0%, p = 0.008), and less likely to have attained a university or postgraduate level of education (31.2% vs. 45.6%, p < 0.001), or to have an annual income of ≥£30,000 (18.2% vs. 32.9%, p < 0.001). They were more likely to report urgency (44.6% vs. 19.1%, p < 0.001) as their most troublesome symptom and a greater proportion had severe IBS symptom scores, abnormal depression scores, higher somatic symptom-reporting scores or higher gastrointestinal symptom-specific anxiety scores (p < 0.01 for trend for all analyses). Mean health-related quality of life scores were significantly lower among those with, compared with those without, FI (p < 0.001). Finally, FI was associated with higher IBS-related direct healthcare costs (p = 0.002).
Conclusions: Among individuals with Rome IV IBS, one-in-four repo rted FI according to Rome IV criteria. Physicians should ask patients with IBS about FI routinely.
Keywords: faecal incontinence; irritable bowel syndrome; quality of life.
© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options!Aliment Pharmacol Ther. 2023 May;57(10):1174-1175. doi: 10.1111/apt.17486. Aliment Pharmacol Ther. 2023. PMID: 37094309 No abstract available.
-
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply.Aliment Pharmacol Ther. 2023 May;57(10):1176-1177. doi: 10.1111/apt.17494. Aliment Pharmacol Ther. 2023. PMID: 37094322 No abstract available.
-
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' reply.Aliment Pharmacol Ther. 2023 Jul;58(1):139-140. doi: 10.1111/apt.17571. Aliment Pharmacol Ther. 2023. PMID: 37307551 No abstract available.
-
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome.Aliment Pharmacol Ther. 2023 Jul;58(1):137-138. doi: 10.1111/apt.17559. Aliment Pharmacol Ther. 2023. PMID: 37307559 No abstract available.
Similar articles
-
Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.Neurogastroenterol Motil. 2017 Feb;29(2):10.1111/nmo.12919. doi: 10.1111/nmo.12919. Epub 2016 Aug 31. Neurogastroenterol Motil. 2017. PMID: 27581702 Free PMC article.
-
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.Aliment Pharmacol Ther. 2023 Feb;57(3):323-334. doi: 10.1111/apt.17356. Epub 2022 Dec 21. Aliment Pharmacol Ther. 2023. PMID: 36544055
-
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.Aliment Pharmacol Ther. 2022 Jul;56(1):110-120. doi: 10.1111/apt.16939. Epub 2022 May 1. Aliment Pharmacol Ther. 2022. PMID: 35491477 Free PMC article.
-
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Lancet Gastroenterol Hepatol. 2020. PMID: 32702295
-
Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1097-103. doi: 10.1097/MEG.0b013e3282f1621b. Eur J Gastroenterol Hepatol. 2007. PMID: 17998835 Review.
Cited by
-
New objective scoring system to clinically assess fecal incontinence.World J Gastroenterol. 2023 Aug 7;29(29):4593-4603. doi: 10.3748/wjg.v29.i29.4593. World J Gastroenterol. 2023. PMID: 37621752 Free PMC article.
-
Garg incontinence scores: New scoring system on the horizon to evaluate fecal incontinence. Will it make a difference?World J Gastroenterol. 2024 Jan 21;30(3):204-210. doi: 10.3748/wjg.v30.i3.204. World J Gastroenterol. 2024. PMID: 38314129 Free PMC article. Review.
-
Digital Gut-Directed CBT May Improve Fecal Incontinence in IBS.Dig Dis Sci. 2025 Apr;70(4):1441-1448. doi: 10.1007/s10620-025-08871-w. Epub 2025 Feb 14. Dig Dis Sci. 2025. PMID: 39953183
-
Faecal incontinence with concurrent disorders of gut-brain interaction: A worse outcome.United European Gastroenterol J. 2024 May;12(4):496-503. doi: 10.1002/ueg2.12541. Epub 2024 Feb 27. United European Gastroenterol J. 2024. PMID: 38412024 Free PMC article.
-
Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction.Nat Rev Gastroenterol Hepatol. 2025 Apr;22(4):228-251. doi: 10.1038/s41575-024-01033-9. Epub 2025 Jan 27. Nat Rev Gastroenterol Hepatol. 2025. PMID: 39870943 Review.
References
REFERENCES
-
- Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17.
-
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133-46.
-
- Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-407.
-
- Staller K, Olen O, Soderling J, Roelstraete B, Törnblom H, Khalili H, et al. Mortality risk in irritable bowel syndrome: results from a Nationwide prospective cohort study. Am J Gastroenterol. 2020;115(5):746-55.
-
- Chang JY, Locke GR 3rd, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822-32.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous